KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Other Non Operating Income (2018 - 2025)

Historic Other Non Operating Income for Moderna (MRNA) over the last 8 years, with Q2 2025 value amounting to $8.0 million.

  • Moderna's Other Non Operating Income rose 12962.96% to $8.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$25.0 million, marking a year-over-year increase of 7422.68%. This contributed to the annual value of -$87.0 million for FY2024, which is 2983.87% up from last year.
  • Moderna's Other Non Operating Income amounted to $8.0 million in Q2 2025, which was up 12962.96% from -$4.0 million recorded in Q1 2025.
  • Moderna's 5-year Other Non Operating Income high stood at $14.0 million for Q2 2023, and its period low was -$51.0 million during Q3 2023.
  • Moreover, its 5-year median value for Other Non Operating Income was -$12.0 million (2022), whereas its average is -$15.6 million.
  • Per our database at Business Quant, Moderna's Other Non Operating Income crashed by 90000.0% in 2021 and then skyrocketed by 20769.23% in 2023.
  • Quarter analysis of 5 years shows Moderna's Other Non Operating Income stood at -$7.0 million in 2021, then crashed by 71.43% to -$12.0 million in 2022, then tumbled by 225.0% to -$39.0 million in 2023, then rose by 25.64% to -$29.0 million in 2024, then soared by 127.59% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q2 2025, -$4.0 million for Q1 2025, and -$29.0 million during Q4 2024.